Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133877) titled 'A single-arm, multicenter, prospective clinical study of irinotecan hydrochloride liposomal(II) in combination with apatinib in the treatment of patients with recurrent small cell lung cancer and liver metastasis' on Oct. 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Harbin Medical University cancer Hospital
Condition:
Recurrent small cell lung cancer with liver metastasis
Intervention:
Intervention group:Liposomal irinotecan (II): 60-80 mg/m^2, intravenous infusion over 90 minutes, D1, once every two weeks. The starting dose of liposomal irinotecan is 60 mg/m^2
Recruitment...